

Gromacs/pmx for large scale alchemical protein-ligand binding affinity screening

Vytautas Gapsys
vgapsys@gwdg.de

Max Planck Institute for Multidisciplinary Sciences

Computational Biomolecular Dynamics Group (Dr. Bert de Groot)

April 21, 2022

Computational Alchemy

- Molecular dynamics based method
- Free energy calculation


Introduction: Molecular Dynamics simulations

Molecular Dynamics simulations

- Thermostat: scale velocities
- Barostat: scale box dimensions
- Integrate equations of motion over time

System setup

- Fully atomistic representation
- Explicit solvation
- Ions



Introduction: Molecular Dynamics simulations

Introduction: Molecular Dynamics simulations

Molecular dynamics simulations

- Well defined statistical ensembles
- Atomistic resolution

Aim

Calculate change in thermostability due to a mutation.


Alchemical Methods

Aim

Calculate change in thermostability due to a mutation.

Counting

- Simulate the process of folding the WT protein.
- Count folded/unfolded states.
- Extract $\Delta G_{\text{folding}}^{\text{WT}}$ from the frequencies.



Alchemical Methods

Aim

Calculate change in thermostability due to a mutation.

Counting


- Do the same for the MUT protein:

$$\Delta\Delta G = \Delta G_{\text{folding}}^{\text{MUT}} - \Delta G_{\text{folding}}^{\text{WT}}$$

WT unfolded protein



$\Delta G_{\text{folding}}^{\text{WT}}$




WT folded protein

MUT unfolded protein



$\Delta G_{\text{folding}}^{\text{MUT}}$



MUT folded protein


Alchemical Methods

Problem



Folding simulations are computationally expensive.

Alchemical solution


- Traverse the thermodynamic cycle in the horizontal directions.
- Use a modified hamiltonian:
 $H(\lambda) = (1 - \lambda)H_0 + \lambda H_1$.
- The same double free energy difference is recovered:
 $\Delta\Delta G = \Delta G_{mutation}^{folded} - \Delta G_{mutation}^{unfolded}$




Alchemical Methods




Gromacs/pmx based alchemy



Amino acid mutations




Nucleotide mutations



Ligand modifications

Relative Protein-Ligand binding free energy



Protein-Ligand binding

Calculation of the Relative Change in Binding Free Energy of a Protein-Inhibitor Complex

PAUL A. BASH,^{*} U. CHANDRA SINGH,[†] FRANK K. BROWN,[‡]
ROBERT LANGRIDGE, PETER A. KOLLMAN

By means of a thermodynamic perturbation method implemented with molecular dynamics, the relative free energy of binding was calculated for the enzyme thermolysin complexed with a pair of phosphoramidate and phosphonate ester inhibitors. The calculated difference in free energy of binding was 4.21 ± 0.54 kilocalories per mole. This compares well with the experimental value of 4.1 kilocalories per mole. The method is general and can be used to determine a change or "mutation" in any system that can be suitably represented. It is likely to prove useful for protein and drug design.

TI for a single free energy value. Science, 1987

J | A | C | S
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Article
pubs.acs.org/JACS

Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field

Lingle Wang,[†] Yujie Wu,[†] Yuqing Deng,[†] Byungchan Kim,[†] Levi Pierce,[†] Goran Krilov,[†] Dmitry Lupyan,[†] Shaughnessy Robinson,[†] Markus K. Dahlgren,[†] Jeremy Greenwood,[†] Donna L. Romero,[‡] Craig Masse,[‡] Jennifer L. Knight,[†] Thomas Steinbrecher,[†] Thijs Beumung,[†] Wolfgang Damm,[†] Ed Harder,[†] Woody Sherman,[†] Mark Brewer,[†] Ron Wester,[†] Mark Murcko,[†] Leah Frye,[†] Ramy Farid,[†] Teng Lin,[†] David L. Mobley,[†] William L. Jorgensen,[§] Bruce J. Berne,[§] Richard A. Friesner,[†] and Robert Abel^{*†}

[†]Schrödinger, Inc., 120 West 45th Street, New York, New York 10036, United States

[‡]Nimbus Discovery, 25 First Street, Suite 404, Cambridge, Massachusetts 02141, United States

[§]Department of Chemistry, Columbia University, 3000 Broadway, New York, New York 10027, United States

[†]Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States


^{*}Departments of Pharmaceutical Sciences and Chemistry, University of California—Irvine, Irvine, California 92697, United States

FEP for 330 relative free energies. JACS, 2015

Application:
482 ligand modifications in protein-ligand binding

*Gapsys, Perez-Benito, Aldeghi, Seeliger, van Vlijmen, Tresadern, de Groot,
Chemical Science, 2020*

Protein-Ligand complexes



PDE2: 21 ligand
34 perturbations



Galectin: 8 ligands
8 perturbations




cMet: 12 ligands
25 perturbations



BACE: 80 ligands
144 perturbations
(divided in 3 sets)

■ 11 systems


■ 482 mutations




JNK1: 21 ligands
31 perturbations




TYK2: 16 ligands
24 perturbations




MCL1: 42 ligands
71 perturbations




CDK2: 16 ligands
25 perturbations



Thrombin: 11 ligands
16 perturbations




PTP1b: 23 ligands
49 perturbations




P38: 34 ligands
56 perturbations

Overall results



Results: by case



High throughput $\Delta\Delta G$ calculations


Gapsys, Hahn, Tresadern, Mobley, Rampp, de Groot, JCIM, 2022
Kutzner, Kniep, Cherian, Nordstrom, Grubmüller, de Groot, Gapsys, JCIM, 2022

Large-Scale Assessment of Binding Free Energy Calculations in Active Drug Discovery Projects

Christina E. M. Schindler,* Hannah Baumann, Andreas Blum, Dietrich Böse, Hans-Peter Buchstaller, Lars Burgdorf, Daniel Cappel, Eugene Chekler, Paul Czodrowski, Dieter Dorsch, Merveille K. I. Eguida, Bruce Follows, Thomas Fuchß, Ulrich Grädler, Jakub Gunera, Theresa Johnson, Catherine Jorand Lebrun, Srinivasa Karra, Markus Klein, Tim Knehans, Lisa Koetzner, Mireille Krier, Matthias Leiendecker, Birgitta Leuthner, Liwei Li, Igor Mochalkin, Djordje Musil, Constantin Neagu, Friedrich Rippmann, Kai Schiemann, Robert Schulz, Thomas Steinbrecher, Eva-Maria Tanzer, Andrea Unzue Lopez, Ariele Viacava Follis, Ansgar Wegener, and Daniel Kuhn*

Benchmark dataset assembled by Merck KGaA

High throughput $\Delta\Delta G$ calculations



- 8 systems


- >500 $\Delta\Delta G$

- >200 μs simulation

- 3 force fields


- 3 independent replicas for each calculation

High throughput $\Delta\Delta G$ calculations




- MPCDF cluster Raven
- Using 480 nodes simultaneously (46k cores)
- 3 days of calculations: 3.4 million core hours


High throughput $\Delta\Delta G$ calculations




High throughput $\Delta\Delta G$ calculations




ΔΔG calculation in the cloud




$\Delta\Delta G$ calculation in the cloud




ΔΔG calculation in the cloud



AWS costs for $\Delta\Delta G$ calculation



Absolute protein-ligand binding ΔG



Absolute protein-ligand binding ΔG


Absolute protein-ligand binding ΔG : Part 1

Explore applicability of FEP, HREX-FEP and
Non-equilibrium approaches


Gapsys, Yildirim, Aldeghi, Khalak, van der Spoel, de Groot, Commun. Chem., 2021

Non-equilibrium free energy calculation protocol


Equilibrium FEP




State A ($\lambda=0$)




State B ($\lambda=1$)




Non-Equilibrium TI




State A ($\lambda=0$)




State B ($\lambda=1$)



Absolute ΔG




Studied systems



BRD4(1) specificity


11 ligands




Ligand 1




Ligand 2



Ligand 3




Ligand 4



Ligand 5



Ligand 6



Ligand 7



Ligand 8



Ligand 9




Ligand 10




Ligand 11


BRD4(1)




BRD4(1) specificity: overall accuracy



Bromosporine





Bromosporine




22 proteins

Bromosporine: overall accuracy





T4 Lysozyme (L99A)





- Apo and Holo states differ significantly
- *Lim, Wang, Abel, Mobley, 2016, JCTC* observed that long FEP simulations needed to converge $\Delta\Delta G$
- Non-equilibrium method allows combining different Apo and Holo states

T4 Lysozyme



T4 Lysozyme



Summary: absolute ΔG Part 1

Non-equilibrium approach

- Can be used for absolute ΔG
- Converges faster than FEP, comparably to HREX-FEP
- Allows taking into account Apo and Holo conformations


Absolute protein-ligand binding ΔG : Part 2

Large scale absolute protein-ligand binding free energies

Khalak, Treadern, Aldeghi, Baumann, Mobley, de Groot, Gapsys, Chem. Sci., 2021

Method

- Do not simulate protein-ligand complex with the decoupled ligand
- Place a proper ligand ensemble into the apo protein ensemble



Protein-Ligand complexes

■ 7 systems

■ 128 ligands


Data sets from:
*Gapsys, Perez-Benito,
et al, Chemical Science,
2020*



PDE2: 21 ligand
34 perturbations




Galectin: 8 ligands
7 perturbations




cMet: 12 ligands
25 perturbations



BACE: 80 ligands
144 perturbations
(divided in 3 sets)



JNK1: 21 ligands
31 perturbations



TYK2: 16 ligands
24 perturbations




MCL1: 42 ligands
71 perturbations




CDK2: 16 ligands
25 perturbations



Thrombin: 11 ligands
16 perturbations




PTP1b: 23 ligands
49 perturbations




P38: 34 ligands
56 perturbations


Overall results




The importance of the apo structure




The importance of the apo structure




A case study: p38




A case study: p38





A case study: p38



A case study: p38




A case study: p38



Summary: absolute ΔG Part 2


ABFE

- It is essential to capture ΔG between apo and holo protein conformers
- Absolute ΔG accuracy comparable to that of RBFE
- Comes at a higher computational cost





GROMACS
FAST. FLEXIBLE. FREE.



pmx

Dr. Daniel Seeliger

Dr. Matteo Aldeghi

Dr. Servaas Michielssens

Dr. Yuriy Khalak

Professor Dr. Bert de Groot

Protein-Ligand binding

Dr. Laura Perez-Benito

Dr. Gary Tresadern

Dr. David Hahn

Dr. Ahmet Yildirim

Hannah Baumann

Professor Dr. David Mobley

Professor Dr. David van der Spoel

Professor Dr. Herman van Vlijmen

AWS and HPC

Dr. Carsten Kutzner

Dr. Markus Rampp

Christian Kniep

Austin Cherian

Ludvig Nordstrom

Funding



MAX-PLANCK-GESellschaft



Boehringer
Ingelheim